Why is Brawn Biotech falling/rising?

As of 25-Aug, Brawn Biotech Ltd's stock price is currently at 20.80, reflecting an increase of 0.96 or 4.84%. The stock has shown strong performance recently, gaining 10.05% over the last two days and outperforming its sector by 4.83% today. It is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating positive momentum. Despite a year-to-date decline of 2.39%, the stock has delivered a 14.16% return over the past year, showcasing its ability to generate returns even when the broader market has struggled. However, concerns about long-term fundamental strength persist, as evidenced by a weak average Return on Equity (ROE) of 0% and declining net sales and operating profit over the last five years.
In the broader market context, Brawn Biotech's recent performance stands in stark contrast to the benchmark Sensex, which has only gained 0.45% over the past week and 0.21% over the past month. While the stock has outperformed the market significantly in the short term, the overall market has generated negative returns of -2.11% over the last year, highlighting the stock's relative strength. Nonetheless, the company's weak long-term growth prospects and negative EBITDA raise concerns about its sustainability, suggesting that while the stock is currently rising, it faces significant risks that could impact its future performance.